Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an announcement.
Grand Pharmaceutical Group Limited has declared a final ordinary cash dividend of HKD 0.169 per share for the financial year ended 31 December 2025, underscoring its continued commitment to shareholder returns. The proposed payout, subject to shareholder approval on 5 June 2026, will be distributed on 30 June 2026 to investors on the register as of 16 June, reinforcing the company’s capital distribution track record and offering income visibility for its equity holders.
The stock will trade ex-dividend on 12 June 2026, with the books closing on 16 June 2026 to determine dividend entitlements. The announcement, which specifies that no withholding tax applies to the dividend, may enhance the stock’s appeal to income-focused investors and signals confidence from the board in the group’s financial performance for the 2025 fiscal year.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$8.50 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Hong Kong-listed company in the healthcare and pharmaceutical sector. It is primarily engaged in the development, manufacture and sale of pharmaceutical products and related healthcare offerings for the China and broader Asian markets, serving both hospital and retail channels as part of the region’s growing medical and wellness industry.
Average Trading Volume: 5,164,934
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.64B
See more insights into 0512 stock on TipRanks’ Stock Analysis page.